Reimbursement Review Reports


( Last Updated : July 27, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Sort descending Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Afinitor Everolimus Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin Reimburse with clinical criteria and/or conditions Complete May 30, 2016 Dec 1, 2016
Afinitor Everolimus Advanced Breast Cancer Reimburse with clinical criteria and/or conditions Complete Sep 5, 2012 Mar 25, 2013
Alecensaro Alectinib Locally advanced or metastatic ALK+ NSCLC (first line) Reimburse with clinical criteria and/or conditions Complete Jan 15, 2018 Jul 25, 2018
Alecensaro Alectinib Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete Aug 18, 2017 Mar 29, 2018
Alecensaro Alectinib Non-Small Cell Lung Cancer Do not reimburse Complete Oct 3, 2016 May 4, 2017
Alimta Pemetrexed Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete May 31, 2013 Nov 19, 2013
Alunbrig Brigatinib NSCLC Do not reimburse Complete Dec 5, 2018 Aug 1, 2019
Alunbrig Brigatinib (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) Complete Sep 30, 2020 Apr 21, 2021
Arzerra Ofatumumab Chronic Lymphocytic Leukemia Do not reimburse Complete Apr 14, 2014 Jan 29, 2015
Atriance Nelarabine Cancelled